Growth and Expansion

As a pharmaceutical company, Sebela Pharmaceuticals is a market leader in gastroenterology, colorectal cancer prevention, dermatology and women’s health. We have the #1 prescribed branded bowel prep kit, the #1 prescribed brand for interdigital tinea pedis, and the #1 prescribed branded hemorrhoid treatment by gastroenterologists and colorectal surgeons.1

Sebela Pharmaceuticals is optimally positioned for continued growth organically and through acquisitions, in-licensing and partnering. We are focused on:

  • Acquiring patent-protected, marketed assets within our core therapeutic areas
  • Licensing or investing in late-stage development (P2B – P3) product opportunities with proven clinical targets within our core therapeutic areas

Partner With Us

At Sebela Pharmaceuticals, we are focused on therapies that can be effectively marketed through a targeted sales force. In addition to growing the products within our existing portfolio, we are actively looking to acquire or in-license commercialized and late-stage development products in the following categories:

  • Gastroenterology
  • Colorectal Cancer Prevention
  • Dermatology
  • Women’s health

To discuss commercial or business development opportunities, please contact us using the form below:

    REFERENCE: 1. IQVIA. National Prescription Audit Report. March 2021.